VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the field

In this video, Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the recent approval of pemigatinib for the treatment of patients with relapsed/refractory (R/R) myeloid/lymphoid neoplasms with FGFR1 rearrangement. Dr Bose highlights the challenges of treating these patients and further explains the impact of this approval in the field. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter